An unfortunate aspect of our legal system is that many important legal issues are not resolved by the courts because a controversy is not only too big to try, but also too big to be filed. A good example is federal-government-threatened civil and criminal claims against pharmaceutical manufacturers for “off-label” promotion, i.e., promotion of pharmaceutical products for uses other than those described on their FDA-approved labeling. Pre-litigation settlements in these cases are negotiated in the shadow of the law and, lacking a robust set of court decisions on the scope of liability, potential defendants are bludgeoned into settlements because of substantial uncertainty over the scope of legitimate claims that could result in, effectively, near death sentences. Not surprisingly, in this environment, manufacturers facing threatened off-label marketing prosecution have agreed to enormous settlement payments, recently as large as $3 billion.
To view this content, please continue to Lexis Advance®.
Not a Lexis Advance® Subscriber? Subscribe Now
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
For questions call 1-877-256-2472 or contact us at email@example.com